APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-07-28

Price

$134.17

-0.08%

This is the 2026-07-28 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score5.6Watchlist

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading as a classic merger arbitrage play following the definitive agreement that AbbVie will acquire the company for $135.11 per share in cash. The strong technical signals (SURGE, ALPHA_MALE, STEADY_CLIMB) and the exceptionally low annualized volatility of 2.4% are directly reflecting the stock pinning just below the acquisition price as the spread narrows. Under the current CAUTION (EARNINGS) macro regime, APGE serves as a safe-haven cash proxy for institutions, completely decoupled from broader tech-heavy market anxieties and rate decision fears.

Fired Signals

SURGEALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Actionable Thesis: APGE is a pure merger arbitrage play offering a highly defensive, low-volatility yield as it slowly drifts toward the $135.11 AbbVie cash acquisition price.
Key Risk: The primary risk is a deal collapse or delay due to FTC antitrust scrutiny or unexpected regulatory hurdles before the expected Q3 2026 close.
What to Watch: Monitor the $132.73 support level; a significant break below this 20-day closing low would indicate institutional doubt regarding the deal's successful completion.

← Back to 2026-07-28 View Full APGE History →Yahoo Finance &nearr;